NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
#Partners
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
#Investment
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
#Investment
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
#Investment
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
#Partners
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
#Investment
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
#Investment
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
#Public Trading
NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
#Investment #Partners
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
#Partners #Expand
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
#Public Trading
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
#Investment
We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
#Investment
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
#Investment #Partners
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
#Investment
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
#Investment #Partners
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
#Investment #Expand
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
#Investment, Management Changes
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
#Customers #Partners
NeuroSense Therapeutics to Participate in BIO-Europe Fall
#Partners
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
undefined
NeuroSense CEO Provides Q3 2023 Update
undefined
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
undefined
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now
undefined
NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results
undefined
European Medicines Agency Grants NeuroSense SME Status
undefined
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
#Investment
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.
undefined
NeuroSense to Host Investor Webinar on September 12, 2023
undefined
NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update
undefined
NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
#Investment #Partners
NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit
#Partners #Expand
NeuroSense CEO Provides Q2 2023 Update
null
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
#Investment
NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
#Investment #Partners #Expand
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
#Customers
NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study
#Customers
NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
#Customers #Partners
NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
#Partners
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
undefined
NeuroSense Announces Year End 2022 Financial Results and Provides Business Update
#Investment #Partners #Management Changes
NeuroSense Therapeutics to Participate in BIO-Europe Spring
#Partners
NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023
#Investment
NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
undefined
Here's Why We're Watching NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Situation
undefined
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
undefined
NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
#Customers
NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study
#Customers
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study
#Investment
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
undefined
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS
#Customers #Partners
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study
undefined
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
#Partners #Expand
NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany
#Partners
NeuroSense Therapeutics and NeuraLight collaborate to detect ALS using AI CTech
undefined
NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study
#Customers
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS BioSpace
#Customers
NeuroSense Therapeutics Granted Key Patent for its ALS Drug PrimeC in Australia
#Customers
NeuroSense Therapeutics Announces Closing of Initial Public Offering on Nasdaq Capital Market
#Public Trading
NeuroSense Therapeutics Publicly Files Registration Statement with SEC for Proposed U.S. Initial Public Offering
#Public Trading
נוירוסנס הישראלית תנפיק בנאסד"ק כדי להיאבק באחת המחלות הקטלניות ביותר
undefined
נוירוסנס תרפיוטיקס באתגר דלי הקרח: גיוס מקדים לפי שווי 80 מיליון דולר
#Investment #Public Trading
Hillel's Tech Corner: NeuroSense: What ALS patients deserve
undefined
NeuroSense Therapeutics Announces Continuation of Positive Trends in Clinical Study in ALS
#Customers
PrimeC Shows Potential to Slow ALS Progression, Interim Data Reveal
#Investment #Expand
NeuroSense Therapeutics Announces Encouraging Interim Results of Clinical Study in ALS
#Investment
NeuroSense Therapeutics Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis (ALS) Drug, and Announces Initiation of Two Clinical Studies in ALS BioSpace
#Customers
ALS Drug Developer NeuroSense Crowdfunds $1.15 Million
#Investment
"You're an entrepreneur, if ALS has no cure, find one"
#Investment
https://www.jpost.com/HEALTH-SCIENCE/Meet-the-Israeli-company-optimistic-about-beating-ALS-580232?fbclid=IwAR0Sz2xC_z3nGUkcyNkYF8V6YQlDHvP2sEVuQmTJ6oEqLjq6HO5ST19XVZE
#Customers #Investment
NeuroSense to develop ALS treatment
#Investment